Navigation Links
Publication Confirms that EpCAM, the Target for Two of Micromet's,Product Candidates, Is Overexpressed on Cancer Stem Cells of,Certain Cancers

didates may be capable of finding and eradicating cancer stem cells in various indications," commented Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "In addition, EpCAM is also expressed on the progeny of cancer stem cells, which may lead to a reduction of tumor mass by these drugs alone or by combining them with standard therapies."

    References

    1  Dalerba P, Dylla SJ, Park I-K et al. Phenotypic characterization of

       human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;

       104:10158-63

    2  Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and

       expansion of human colon-cancer-initiating cells. Nature 2007;

       445: 111-15

    3  Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective

       identification of tumorigenic breast cancer cells. Proc Natl Acad Sci

       USA 2003; 100: 3983-88

    4  Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer

       stem cells. Cancer Res 2007; 67: 1030-7

    5  Collins AT, Berry PA, Hyde C et al. Prospective identification of

       tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51

    6  Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the

       treatment of cancer. Future Oncol 2006; 2: 723-31

    7  Baeuerle PA, Gires 0. EpCAM (CD326) finding its role in cancer. Brit J

       Cancer 2007; 96: 417-23

    8  Went P, Vasei M, Bubendorf L et al. Frequent high-level expression of

       the immunotherapeutic target Ep-CAM in colon, stomach, prostate and

       lung cancers. Br J Cancer 2006; 94: 128-135

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first pro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:5/23/2013)... May 23, 2013  The need to add ... continuum was highlighted prominently at the 108 th ... (AUA), in San Diego.  According to SonaCare Medical, ... ultrasound (HIFU) technology, the need for image-guided technologies ... urologists to consider minimally invasive ablative treatments, was ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... director of the Huntington Hospital Cancer Center, performed the first ... week. In a typical resection there are three ports ... across the belly in an open procedure. , ... offer shorter lengths of stay, less pain and quicker return ...
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9
(Date:5/23/2013)... Winter Park, FL (PRWEB) May 23, 2013 ... 7 Day Belly Blast Diet to determine what makes ... diets. , The published review highlights three main components ... metabolic rate; achieving a positive mindset and the personal ... change calorie intake every 7 days to keep the ...
(Date:5/23/2013)... Denise Mann HealthDay Reporter , , THURSDAY, May ... Americans take to help treat hip and knee osteoarthritis ... risk for developing glaucoma, a small new study of ... is an increase of intraocular pressure (IOP) or pressure ... the leading causes of blindness. In ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 “Talk. They ... campaign that empowers parents to talk to children as ... underage drinking, was launched today by the Substance Abuse ... kickoff occurred in conjunction with SAMHSA’s 2013 National Prevention ... and action around, substance abuse and mental health issues. ...
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... provides important new alternative for patientsRESEARCH TRIANGLE PARK, N.C., ... announced today that the U.S. Food and Drug Administration ... Lamictal ODT uses a novel drug-delivery formulation ... has a pleasant taste and disintegrates on the tongue. ...
... GRAND RAPIDS, Mich., May 11 Lambert, ... Aspirus, Inc. to its growing roster of health care ... Wausau, Wis. providing health care services to residents in ... Aspirus Wausau Hospital is consistently recognized as one ...
... jointly announce a strategic alliance created to provide clients with contract ... ... and Chennai, India (PRWEB) - Dalton Pharma Services and ProCitius Research ... contract chemistry services of exceptional value. , , , ...
... New HHS Report Released During National Women,s Health Week ... A new report released today on gender-based differences in ... as men to suffer from major depression. The ... including the effect trauma and violence can have on ...
... more likely than men to feel the pinch of ... half (52%) of working-age women reporting problems accessing needed ... men, a new Commonwealth Fund study finds. Women who ... 69 percent of underinsured women have problems accessing care ...
... neck injuries , , SUNDAY, May 10 (HealthDay News) -- ... neck injuries related to recreational or work activities outdoors, ... States, about 1.5 million people are treated in hospital ... treated for neck fractures, according to the Consumer Product ...
Cached Medicine News:Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 2Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 3Health News:Ladders, Swings and More Can Cause Peril 2
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Medicine Products: